Skip to main content
FDA Shortage Check

Is Kyxata (Carboplatin Injection) in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Kyxata: in shortage (FDA, Oct 24)

Injections (vials)
A generic injection, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Delay in shipping of the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Demand increase for the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Estimate: “Estimated recovery: TBD/ NDC non-Exempt”. Manufacturer’s estimate, Accord Healthcare Inc., Oct 17, 2026
DRUG
Kyxata
FDA LISTING
FORM
injection
STATUS
Currently in Shortage
FIRST POSTED
Apr 28, 2023
LAST FDA UPDATE
Oct 21, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 29 presentations: 12 unavailable · 8 limited · 9 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Carboplatin Injection. 35 presentations from 9 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Accord Healthcare Inc.4 presentations · 4 unavailable

Contact (FDA's listing): 866-941-7875, option 2

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)

    Estimated recovery: TBD/ NDC non-Exempt

    NDC 16729-295-12Reverified

    Unavailable

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)

    Estimated recovery: TBD/ NDC non-Exempt

    NDC 16729-295-31Reverified

    Unavailable

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)

    Estimated recovery: TBD/ NDC non-Exempt

    NDC 16729-295-33Reverified

    Unavailable

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)

    Estimated recovery: TBD/ NDC non-Exempt

    NDC 16729-295-34Reverified

    Unavailable

Eugia US LLC2 presentations · 1 unavailable · 1 available or not stated

Contact (FDA's listing): 888-238-7880

  • 450 mg/45 mL

    Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)

    On backorder. Recovery: late-October 2026. Check wholesalers for inventory

    NDC 55150-335-01Revised

    Unavailable

  • 600 mg/60 mL

    Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)

    Check wholesalers for inventory

    NDC 55150-386-01Reverified

    Available

Fresenius Kabi USA, LLC1 presentation · 1 unavailable

Contact (FDA's listing): 888-386-1300

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)

    Next release December 2026. Check wholesalers for inventory.

    NDC 63323-172-60Revised

    Unavailable

Gland Pharma Limited4 presentations · 1 unavailable · 2 limited · 1 available or not stated

Contact (FDA's listing): Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270

  • 50mg/5mL

    Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)

    Discontinued; Distributed by BPI Labs, LLC

    NDC 54288-164-01Reverified

    Unavailable

  • 450mg/45mL

    Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)

    Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC

    NDC 54288-166-01Reverified

    Limited Availability

  • 600 mg/65 mL

    Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)

    Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC

    NDC 54288-167-01Reverified

    Limited Availability

  • 150mg/15mL

    Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)

    Distributed by BPI Labs, LLC

    NDC 54288-165-01Reverified

    Available

Hospira, Inc., a Pfizer Company8 presentations · 4 unavailable · 4 limited

Contact (FDA's listing): 844-646-4398

  • 150 mg/15 mL (10 mg/mL)

    Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)

    Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 61703-150-05Revised

    Unavailable

  • 450 mg/45 mL (10 mg/mL)

    Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)

    Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 61703-262-05Revised

    Unavailable

  • 50 mg/5 mL (10 mg/mL)

    Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)

    Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 61703-360-18Revised

    Unavailable

  • 600 mg/60 mL (10 mg/mL)

    Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)

    Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 61703-600-05Revised

    Unavailable

  • 150 mg/15 mL (10 mg/mL)

    Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)

    Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 61703-339-22Revised

    Limited Availability

  • 450 mg/45 mL (10 mg/mL)

    Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)

    Limited Supply Available. Next Delivery and Estimated Recovery: December 2026

    NDC 61703-339-50Revised

    Limited Availability

  • 50 mg/5 mL (10 mg/mL)

    Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)

    Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027

    NDC 61703-339-18Revised

    Limited Availability

  • 600 mg/60 mL (10 mg/mL)

    Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)

    Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 61703-339-56Revised

    Limited Availability

Teva Pharmaceuticals USA, Inc.4 presentations · 1 unavailable · 2 limited · 1 available or not stated

Contact (FDA's listing): 800-545-8800

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)

    Estimated recovery: January 2027

    NDC 0703-4244-01Reverified

    Unavailable

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)

    Estimated recovery: December 2028

    NDC 0703-4239-01Reverified

    Limited Availability

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)

    Estimated recovery: March 2027

    NDC 0703-4248-01Revised

    Limited Availability

  • 10 mg/1 mL

    Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)

    NDC 0703-4246-01Revised

    Available

Avyxa Pharma, LLC2 presentations · 2 available or not stated

Contact (FDA's listing): 877-595-7337; customerservice@avyxa.com

  • 500 mg/50 mL (10 mg/mL)

    Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)

    NDC 83831-142-50Reverified

    Available

  • 80 mg/8 mL (10 mg/mL)

    Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)

    NDC 83831-141-08Reverified

    Available

Teyro Labs4 presentations · 4 available or not stated

Contact (FDA's listing): Natco Pharma USA LLC: (201)786-6500

  • 150 mg/15 mL

    Carboplatin, Injection, 150 mg/15 mL (NDC 69339-365-15)

    Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC)

    NDC 69339-365-15New

    Available

  • 450 mg/45 mL

    Carboplatin, Injection, 450 mg/45 mL (NDC 69339-366-45)

    Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC)

    NDC 69339-366-45New

    Available

  • 50 mg/5 mL

    Carboplatin, Injection, 50 mg/5 mL (NDC 69339-364-05)

    Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC)

    NDC 69339-364-05New

    Available

  • 600 mg/60 mL

    Carboplatin, Injection, 600 mg/60 mL (NDC 69339-367-60)

    Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC)

    NDC 69339-367-60New

    Available

What the manufacturers told FDA

  • Accord Healthcare Inc. · ‘Estimated recovery: TBD/ NDC non-Exempt’ · updated Oct 2026
  • Eugia US LLC · ‘On backorder. Recovery: late-October 2026. Check wholesalers for inventory’ · updated Oct 2026
  • Fresenius Kabi USA, LLC · ‘Next release December 2026. Check wholesalers for inventory.’ · updated Oct 2026
  • Gland Pharma Limited · ‘Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Limited Supply Available. Next Delivery and Estimated Recovery: December 2026’ · updated Oct 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Delay in shipping of the drug
  • Demand increase for the drug
  • Discontinuation of the manufacture of the drug
  • Other

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Other products with the same ingredient and form

A discontinuation “does not necessarily create a shortage” (FDA).

  • Ingenus Pharmaceuticals LLC told FDA it will discontinue Carboplatin (posted ).

    “Discontinuation of the manufacture of the drug”

    FDA listing: Carboplatin Injection

  • Teyro Labs told FDA it will discontinue Carboplatin (posted ).

    “Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug”

    FDA listing: Carboplatin Injection

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Kyxata in shortage?
Yes. As of Oct 24, 2026, FDA lists Carboplatin Injection as currently in shortage: 29 presentations, 12 unavailable and 8 limited.
When will the Kyxata shortage end?
FDA gives no end date. 15 presentations carry a manufacturer’s own estimate, quoted on this page with its date.
Does FDA list alternatives to Kyxata?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.